Clinical trial
Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small…
NCT00216216 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00216216 |
|---|---|
| Title | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer |
| Official title | Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78) |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Eli Lilly and Company Industry Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 43 |
| Start date | Jan 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: